Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore

by Cheng Ean Chee, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Jian Yi Choy, Meibo Hu, Amrita Viswambaram, Han Chong Toh
Published 2024

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

by Daniel V. T. Catenacci, Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I. Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A. Moore, Minori Koshiji Rosales, Haeseong Park
Published 2023